carbidopa, levodopa drug combination and apomorphine
carbidopa, levodopa drug combination has been researched along with apomorphine in 23 studies
Research
Studies (23)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 2 (8.70) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Frankel, JP; Hughes, A; Lees, AJ; Stern, GM | 1 |
| Carvey, P; Goetz, CG; Klawans, HL | 1 |
| Casey, DE; Gerlach, J | 1 |
| Blaney, TJ; Chandonait, SE; Emerich, DF; Lindner, MD; Mullins, TD; Plone, MA; Sherman, SS; Stott, JA; Winn, SR | 1 |
| Ghika, J; Solida, A; Vingerhoets, F | 1 |
| Ludin, HP; Surber, Ch | 1 |
| Belavic, J | 1 |
| Worth, PF | 1 |
| Capone, JG; Contini, E; Golfre-Andreasi, N; Gragnaniello, D; Preda, F; Quatrale, R; Sensi, M; Sette, E; Tola, MR; Trevisani, L; Tugnoli, V | 1 |
| Brauer, AF; Ciucci, MR; Kelm-Nelson, CA | 1 |
| Bloem, BR; Faber, MJ; Nijhuis, FA; Post, B; van Heek, J | 1 |
| Borgemeester, R; van Laar, T | 1 |
| Evans, AH; Fung, VSC; Hayes, M; Iansek, R; Kimber, T; O'Sullivan, JD; Sue, CM; Williams, DR | 1 |
| Aasly, J; Dietrichs, E; Egge, A; Ezat, B; Pihlstrøm, L; Tysnes, OB | 1 |
| Mundt-Petersen, U; Odin, P | 1 |
| Antonini, A; Canesi, M; Costanzo, AM; Defazio, G; di Luzio Paparatti, U; Gualberti, G; Latorre, A; Lopiano, L; Marano, P; Melzi, G; Modugno, N; Pontieri, FE; Quatrale, R; Sensi, M; Solla, P; Tambasco, N; Tessitore, A | 1 |
| Eklund, M; Henriksen, T; Nyholm, D; Odin, P; Sahlström, T; Timpka, J | 1 |
| Lees, AJ; Moro, A; Munhoz, RP; Pessoa, RR; Teive, HAG | 1 |
| Centonze, D; Fasano, A; Femiano, C; Lena, F; Modugno, N; Olivola, E; Santilli, M; Varanese, S | 1 |
| Bartig, D; Gold, R; Jörges, C; Jost, W; Krogias, C; Richter, D; Stumpe, B; Tönges, L | 1 |
| McFarthing, K; Prakash, N; Simuni, T | 1 |
| de Bie, RMA; Dijk, JM; Espay, AJ; Katzenschlager, R | 1 |
| Comella, CL; Hauser, RA; LeWitt, PA | 1 |
Reviews
9 review(s) available for carbidopa, levodopa drug combination and apomorphine
| Article | Year |
|---|---|
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Drug Interactions; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Haplorhini; Humans; Levodopa; Lithium; Male; Parasympatholytics; Rats; Receptors, Dopamine; Stereotyped Behavior | 1983 |
[Prevention and treatment of fluctuations in patients with Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Infusion Pumps, Implantable; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2006 |
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease; Patient Selection | 2013 |
The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Administration Routes; Drug Combinations; Gels; Humans; Intestines; Levodopa; Parkinson Disease | 2016 |
Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
Topics: Antiparkinson Agents; Apomorphine; Australia; Carbidopa; Deep Brain Stimulation; Drug Combinations; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2017 |
Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2017 |
Apomorphine in the treatment of Parkinson's disease: a review.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2018 |
The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Clinical Decision-Making; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2020 |
On demand therapy for Parkinson's disease patients: Opportunities and choices.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2021 |
Other Studies
14 other study(ies) available for carbidopa, levodopa drug combination and apomorphine
| Article | Year |
|---|---|
Marijuana for parkinsonian tremor.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Diazepam; Drug Combinations; Humans; Levodopa; Marijuana Smoking; Parkinson Disease; Tremor | 1990 |
Dopamine agonists in clinical research for new tardive dyskinesia treatments.
Topics: Adult; Aged; Antipsychotic Agents; Apomorphine; Benserazide; Carbidopa; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Synaptic Transmission | 1983 |
Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Cell Transplantation; Disease Models, Animal; Dopamine; Drug Combinations; Drug Synergism; Levodopa; Male; Movement Disorders; Neostriatum; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotation | 1997 |
Acute dopaminergic challenge tests to assess postural/kinetic tremor of different origin: a case report.
Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Essential Tremor; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Posture; Receptors, Dopamine | 2002 |
Drugs for treating Parkinson disease.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechols; Drug Combinations; Drugs, Generic; Humans; Indans; Levodopa; Nitriles; Parkinson Disease | 2012 |
Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Drug Administration Routes; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Patient Selection; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome | 2014 |
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Combinations; Fourier Analysis; Levodopa; Male; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Stereotyped Behavior; Time Factors; Ultrasonics; Vocalization, Animal | 2016 |
Choosing an Advanced Therapy in Parkinson's Disease; is it an Evidence-Based Decision in Current Practice?
Topics: Apomorphine; Carbidopa; Caregivers; Clinical Decision-Making; Consumer Health Information; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Evidence-Based Practice; Humans; Levodopa; Neurologists; Parkinson Disease; Patient Preference; Qualitative Research | 2016 |
Use of advanced therapies for Parkinson's disease in Norway.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Utilization; Gels; Healthcare Disparities; Humans; Infusions, Parenteral; Levodopa; Norway; Parkinson Disease; Patient Education as Topic | 2017 |
Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Cost of Illness; Cross-Sectional Studies; Drug Combinations; Family; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Quality of Life; Socioeconomic Factors; Surveys and Questionnaires; Treatment Outcome | 2018 |
Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Denmark; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies; Sweden | 2018 |
Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Carbidopa; Cognitive Dysfunction; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Substitution; Electronic Health Records; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Germany; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Neurology; Parkinson Disease; Practice Patterns, Physicians' | 2019 |
Clinical Trial Highlights - Infusion Therapies.
Topics: Apomorphine; Carbidopa; Clinical Trials as Topic; Dopamine Agonists; Drug Combinations; Gels; Humans; Infusion Pumps, Implantable; Infusions, Subcutaneous; Jejunum; Levodopa; Parkinson Disease | 2020 |